Metoprine

Identification

Name
Metoprine
Accession Number
DB04655
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
UNII
2L9RKX796Q
CAS number
7761-45-7
Weight
Average: 269.13
Monoisotopic: 268.028251754
Chemical Formula
C11H10Cl2N4
InChI Key
VQJHOPSWBGJHQS-UHFFFAOYSA-N
InChI
InChI=1S/C11H10Cl2N4/c1-5-9(10(14)17-11(15)16-5)6-2-3-7(12)8(13)4-6/h2-4H,1H3,(H4,14,15,16,17)
IUPAC Name
5-(3,4-dichlorophenyl)-6-methylpyrimidine-2,4-diamine
SMILES
CC1=C(C(N)=NC(N)=N1)C1=CC(Cl)=C(Cl)C=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UHistamine N-methyltransferaseNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Metoprine.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Metoprine.Experimental
BevacizumabBevacizumab may increase the cardiotoxic activities of Metoprine.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Metoprine.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Metoprine.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Metoprine.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Metoprine.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Metoprine.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Metoprine.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Metoprine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Metoprine.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Metoprine.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Metoprine.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Metoprine.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Metoprine.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Metoprine.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Metoprine.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Metoprine.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Metoprine.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Metoprine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
24466
PubChem Substance
46504679
ChemSpider
22874
BindingDB
50059956
ChEMBL
CHEMBL264373
HET
C2M
PDB Entries
2aov

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0758 mg/mLALOGPS
logP2.87ALOGPS
logP2.65ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)17.21ChemAxon
pKa (Strongest Basic)7.93ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area77.82 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity71.72 m3·mol-1ChemAxon
Polarizability26.07 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9364
Caco-2 permeable+0.7525
P-glycoprotein substrateNon-substrate0.7132
P-glycoprotein inhibitor INon-inhibitor0.9246
P-glycoprotein inhibitor IINon-inhibitor0.9149
Renal organic cation transporterNon-inhibitor0.8355
CYP450 2C9 substrateNon-substrate0.8255
CYP450 2D6 substrateNon-substrate0.9171
CYP450 3A4 substrateNon-substrate0.6777
CYP450 1A2 substrateInhibitor0.859
CYP450 2C9 inhibitorNon-inhibitor0.961
CYP450 2D6 inhibitorNon-inhibitor0.6743
CYP450 2C19 inhibitorNon-inhibitor0.8105
CYP450 3A4 inhibitorNon-inhibitor0.8438
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5478
Ames testNon AMES toxic0.8416
CarcinogenicityNon-carcinogens0.8523
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7098 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9548
hERG inhibition (predictor II)Non-inhibitor0.796
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dichlorobenzenes. These are compounds containing a benzene with exactly two chlorine atoms attached to it.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Halobenzenes
Direct Parent
Dichlorobenzenes
Alternative Parents
Aminopyrimidines and derivatives / Imidolactams / Aryl chlorides / Heteroaromatic compounds / Azacyclic compounds / Primary amines / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives
Substituents
1,2-dichlorobenzene / Aminopyrimidine / Aryl chloride / Aryl halide / Pyrimidine / Imidolactam / Heteroaromatic compound / Azacycle / Organoheterocyclic compound / Organonitrogen compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
a small molecule (CPD-10891)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Histamine n-methyltransferase activity
Specific Function
Inactivates histamine by N-methylation. Plays an important role in degrading histamine and in regulating the airway response to histamine.
Gene Name
HNMT
Uniprot ID
P50135
Uniprot Name
Histamine N-methyltransferase
Molecular Weight
33294.765 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on September 11, 2007 11:49 / Updated on November 09, 2017 03:44